Jan T Kielstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1490424/publications.pdf

Version: 2024-02-01

283 papers 13,468 citations

61 h-index 28297 105 g-index

322 all docs 322 docs citations

times ranked

322

13592 citing authors

#	Article	IF	CITATIONS
1	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). Infection, 2023, 51, 71-81.	4.7	1
2	Effectiveness of CytoSorb in cases of acute amitriptyline intoxication is not proven. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 420-420.	1.5	1
3	Evaluation of the ideal length of the Seldinger needle for internal jugular vein catheter placement. Scientific Reports, 2022, 12, 2745.	3.3	1
4	Is This the Beginning of the End of Cytokine Adsorption?. Critical Care Medicine, 2022, Publish Ahead of Print, .	0.9	7
5	Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity) Tj ETQq1 1	1 8:784314	1 ₂ PBT /Ove
6	MO693: Longitudinal Intraindividual Changes of Peritoneal Histology over Time in 37 Peritoneal Dialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	MO362: Braunschweig Body Composition, Butterfly Sonography and Drug Dosing in AKI Study (B3 D2) Tj ETQq1 1	1 0.784314	4 rgBT /O <mark>ve</mark>
8	Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Critical Care, 2022, 26, .	5.8	18
9	Clearance of chloroquine and hydroxychloroquine by the <scp>Seraph® 100 Microbinda Affinity Blood Filter â€</scp> a device approved for the treatment of <scp>COVID</scp> â€19 patients. Therapeutic Apheresis and Dialysis, 2021, 25, 237-241.	0.9	9
10	Heparin 2.0: A New Approach to the Infection Crisis. Blood Purification, 2021, 50, 28-34.	1.8	69
11	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2021, 14, 277-283.	2.9	1
12	Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis. Transfusion Medicine and Hemotherapy, 2021, 48, 234-239.	1.6	5
13	Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter. TH Open, 2021, 05, e134-e138.	1.4	10
14	Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. Pharmacotherapy, 2021, 41, 463-478.	2.6	4
15	MO669FIRST RESULTS OF THE COVID-19 PATIENTS TREATED WITH THE SERAPH®Â100 MICROBIND®ÂAFFINITY FILTER (COSA) REGISTRY. Nephrology Dialysis Transplantation, 2021, 36, .	⁽ 0.7	2
16	MO444MACROPHAGE DENSITIES CORRELATE WITH LONG-TERM FUNCTION IN PAUCI-IMMUNE AND MEMBRANOUS GLOMERULONEPHRITIS AS WELL AS IN HYPERTENSIVE NEPHROPATHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
17	Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Critical Care, 2021, 25, 201.	5.8	14
18	Hemofiltration with the Seraph® 100 Microbind® Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Critical Care, 2021, 25, 190.	5.8	27

#	Article	lF	Citations
19	Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1256-1257.	4.5	9
20	Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2021, 77, 169-173.	3.0	2
21	Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney International, 2021, 100, 720-736.	5. 2	6
22	Drugs linked to plasma homoarginine in chronic kidney disease patientsâ€"a cross-sectional analysis of the German Chronic Kidney Disease cohort. Nephrology Dialysis Transplantation, 2020, 35, 1187-1195.	0.7	4
23	ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis. Journal of Thrombosis and Thrombolysis, 2020, 49, 67-74.	2.1	13
24	Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney International, 2020, 97, 502-515.	5.2	18
25	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	5.2	8
26	Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 2020, 80, 1-11.	2.2	156
27	In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter. CKJ: Clinical Kidney Journal, 2020, 13, 421-424.	2.9	17
28	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
29	Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Current Hypertension Reports, 2020, 22, 102.	3 . 5	46
30	Elimination of <i>Staphylococcus aureus</i> from the bloodstream using a novel biomimetic sorbent haemoperfusion device. BMJ Case Reports, 2020, 13, e235262.	0.5	21
31	Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter. , 2020, 2, e0180.		37
32	FP567IMPACT OF SAMPLING SIDE OF PERITONEAL BIOPSIES ON PERITONEAL THICKNESS AND HISTOPATHOLOGICAL DIAGNOSIS - A QUANTITATIVE HISTOLOGICAL STUDY IN BODY DONORS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
33	FP599INDIVIDUALIZED FILLING VOLUME IN PD PATIENTS BASED ON INTRAPERITONEAL PRESSURE MEASUREMENT - EFFECT ON ABDOMINAL DISCOMFORT. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
34	FP642INCREASED POSTOPERATIVE ARTERIOVENOUS FISTULA BLOOD FLOW AFTER SWITCHING FROM LOCAL TO REGIONAL ANESTHESIA - A SINGLE CENTER PRE AND POST STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
35	Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2019, 12, 663-672.	2.9	82
36	Single-dose diclofenac in healthy volunteers can cause decrease in renal perfusion measured by functional magnetic resonance imagingâ€. Journal of Pharmacy and Pharmacology, 2019, 71, 1262-1270.	2.4	8

#	Article	IF	Citations
37	The MATRIX trial. Lancet, The, 2019, 393, 1802-1803.	13.7	O
38	Outcomes of renal dysfunction in patients with acute liver failure. United European Gastroenterology Journal, 2019, 7, 388-396.	3.8	16
39	Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 997-1002.	3.0	11
40	International registry on the use of the CytoSorb® adsorber in ICU patients. Medizinische Klinik - Intensivmedizin Und Notfallmedizin, 2019, 114, 699-707.	1.1	78
41	Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury. Scientific Reports, 2018, 8, 3438.	3.3	69
42	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. International Journal of Antimicrobial Agents, 2018, 52, 151-157.	2.5	25
43	Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. BMJ Case Reports, 2018, 2018, bcr-2017-221735.	0.5	2
44	SaO040TREATMENT OF BACTEREMIA DURING DIALYSIS USING A BIOMIMETIC SORBENT HEMOPERFUSION DEVICE - RESULTS OF AN ONGOING FIRST-IN-HUMAN STUDY. Nephrology Dialysis Transplantation, 2018, 33, i332-i333.	0.7	2
45	Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Critical Care, 2018, 22, 285.	5.8	113
46	Preoperative serum uric acid predicts incident acute kidney injury following cardiac surgery. BMC Nephrology, 2018, 19, 161.	1.8	16
47	Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis. BMC Nephrology, 2018, 19, 12.	1.8	24
48	Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. Intensive Care Medicine, 2018, 44, 1483-1492.	8.2	46
49	The Circular RNA ciRs-126 Predicts Survival in Critically Ill Patients With Acute Kidney Injury. Kidney International Reports, 2018, 3, 1144-1152.	0.8	55
50	Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. European Journal of Rheumatology, 2018, 5, 153-159.	0.6	1
51	Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrology Dialysis Transplantation, 2017, 32, 325-332.	0.7	63
52	Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. Journal of Intensive Care, 2017, 5, 12.	2.9	52
53	Have renal biomarkers failed in acute kidney injury? Yes. Intensive Care Medicine, 2017, 43, 883-886.	8.2	6
54	A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine. BMC Nephrology, 2017, 18, 134.	1.8	10

#	Article	IF	CITATIONS
55	Management of patients at risk of acute kidney injury. Lancet, The, 2017, 389, 2139-2151.	13.7	188
56	Pro: High dose of therapeutic plasma exchangeâ€"mind the gap!. Nephrology Dialysis Transplantation, 2017, 32, 1457-1460.	0.7	5
57	The role of laser Doppler flowmetry tests, serum angiopoietin-2, asymmetric and symmetric dimethylarginine to predict outcome in chronic kidney disease. Journal of Hypertension, 2017, 35, 1109-1118.	0.5	9
58	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 280-290.e3.	1.9	6
59	Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin–Mediated Hemolytic Uremic Syndrome. Transfusion Medicine Reviews, 2017, 31, 51-55.	2.0	14
60	Opponent's comments. Nephrology Dialysis Transplantation, 2017, 32, 1463-1464.	0.7	1
61	The answer is blowing in the wind: an uncommon cause for severe ARDS accompanied by circulatory insufficiency requiring extracorporeal membrane oxygenation. BMJ Case Reports, 2017, 2017, bcr2016218079.	0.5	2
62	Dimethylarginines in patients with intracerebral hemorrhage: association with outcome, hematoma enlargement, and edema. Journal of Neuroinflammation, 2017, 14, 247.	7.2	5
63	Health status, renal function, and quality of life after multiorgan failure and acute kidney injury requiring renal replacement therapy. International Journal of Nephrology and Renovascular Disease, 2016, 9, 119.	1.8	10
64	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease $\hat{a} \in \text{``cross-sectional}$ data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology, 2016, 17, 59.	1.8	18
65	lgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation. Transplantation, 2016, 100, 2682-2692.	1.0	20
66	Prolonged Mechanical Ventilation After Lung Transplantation—A Single-Center Study. American Journal of Transplantation, 2016, 16, 1579-1587.	4.7	25
67	Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. Journal of Antimicrobial Chemotherapy, 2016, 71, 2673-2674.	3.0	7
68	Acute interstitial nephritis due to flecainide therapy in the 38th week of pregnancy. BMC Nephrology, 2016, 17, 28.	1.8	3
69	Ultrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance. International Urology and Nephrology, 2016, 48, 561-570.	1.4	8
70	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. International Journal of Infectious Diseases, 2016, 42, 1-3.	3.3	11
71	Neurological Sequelae in Adults After E coli O104. Medicine (United States), 2016, 95, e2337.	1.0	12
72	Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. International Urology and Nephrology, 2016, 48, 133-138.	1.4	49

#	Article	IF	CITATIONS
73	Removal of methadone by extended dialysis using a high cut-off dialyzer: implications for the treatment of overdose and for pain management in patients undergoing light chain removal. Clinical Nephrology, 2016, 85 (2016), 353-357.	0.7	4
74	Saving two lives with one dialysis treatment. Clinical Nephrology, 2015, 84 (2015), 104-107.	0.7	6
75	Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers. BMC Obesity, 2015, 2, 37.	3.1	9
76	Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis*. Critical Care Medicine, 2015, 43, e230-e240.	0.9	37
77	Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension, 2015, 33, 1729-1741.	0.5	366
78	SP374POSSIBLE ROLE OF MICROVASCULAR FUNCTION IN THE CARDIOVASCULAR RISK PREDICTION IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii503-iii503.	0.7	0
79	Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated byEscherichia coliO104:H4. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	3
80	FO023ASYMMETRIC DIMETHYLARGININ INDUCES ENDOTHELIAL DYSFUNCTION VIA MODULATION OF MICRORNA 126. Nephrology Dialysis Transplantation, 2015, 30, iii11-iii12.	0.7	0
81	FP037EFFECT OF THERAPEUTIC PLASMA EXCHANGE ON PLASMA LEVELS AND TOTAL REMOVAL OF ADIPOCYTOKINES AND INFLAMMATORY MARKERS. Nephrology Dialysis Transplantation, 2015, 30, iii76-iii77.	0.7	0
82	FP536RETROSPECTIVE ANALYSIS OF 912 THERAPEUTIC PLASMA EXCHANGES AT A TERTIARY CARE CENTER. Nephrology Dialysis Transplantation, 2015, 30, iii251-iii252.	0.7	0
83	SP070E. COLI O104:H4 INDUCED HUS-OUTBREAK IN GERMANY 2011: SYMPTOMS AND CLINICAL COURSE. Nephrology Dialysis Transplantation, 2015, 30, iii402-iii402.	0.7	0
84	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine, 2015, 66, 165-181.	0.6	98
85	Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. European Heart Journal, 2015, 36, 2184-2196.	2.2	117
86	FP537TREATMENT OF AMITRIPTYLINE INTOXICATIONS BY EXTENDED HIGH-CUT-OFF DIALYSIS - REPORT OF TWO CASES. Nephrology Dialysis Transplantation, 2015, 30, iii252-iii252.	0.7	1
87	Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 50-58.	0.6	37
88	FP280ROLE OF THE ENDOGENOUS NITRIC OXIDE INHIBITOR ADMA AND BDNF IN DEPRESSION AND BEHAVIORAL CHANGES- CLINICAL AND PRECLINICAL DATA IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii161-iii161.	0.7	1
89	Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 1699-1705.	0.7	47
90	Effect of a single dialysis session on cognitive function in CKD5D patients: a prospective clinical study. Nephrology Dialysis Transplantation, 2015, 30, 1551-1559.	0.7	45

#	Article	IF	Citations
91	Circulating Biomarkers for Discrimination Between Aseptic Joint Failure, Low-Grade Infection, and High-Grade Septic Failure. Clinical Infectious Diseases, 2015, 61, 332-341.	5.8	83
92	Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrology Dialysis Transplantation, 2015, 30, 613-621.	0.7	85
93	Ceftolozane-tazobactam versus levofloxacin in urinary tract infection. Lancet, The, 2015, 386, 1241.	13.7	О
94	Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids, 2015, 47, 1983-1993.	2.7	15
95	FP503EFFECT OF EXTENDED DIALYSIS ON SERUM LACTATE AND LACTATE BALANCE IN CRITICALLY ILL PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii239-iii240.	0.7	0
96	Cognitive Function in Patients With Chronic Kidney Disease: Challenges in Neuropsychological Assessments. Seminars in Nephrology, 2015, 35, 304-310.	1.6	28
97	Treatment of amitriptyline intoxications by extended high cut-off dialysis. CKJ: Clinical Kidney Journal, 2015, 8, 796-799.	2.9	8
98	Circulating Long Noncoding RNA TapSAKI Is a Predictor of Mortality in Critically III Patients with Acute Kidney Injury. Clinical Chemistry, 2015, 61, 191-201.	3.2	103
99	Psychiatric Symptoms in Patients with Shiga Toxin-Producing E. coli O104:H4 Induced Haemolytic-Uraemic Syndrome. PLoS ONE, 2014, 9, e101839.	2.5	17
100	The reversible part of cognitive impairment in chronic kidney disease: can mice help men break the TEMPOLimit?. Nephrology Dialysis Transplantation, 2014, 29, 476-478.	0.7	2
101	Total collected dialysate lithium concentration after successful dialysis treatment in case of intoxication. BMC Pharmacology & Expression (2014), 15, 49.	2.4	6
102	Removal Characteristics and Total Dialysate Content of Glutamine and Other Amino Acids in Critically Ill Patients with Acute Kidney Injury Undergoing Extended Dialysis. Nephron Clinical Practice, 2014, 126, 62-66.	2.3	15
103	Guidelines for Reporting Case Studies on Extracorporeal Treatments in Poisonings: Methodology. Seminars in Dialysis, 2014, 27, 407-414.	1.3	68
104	Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study. Transplant International, 2014, 27, 541-552.	1.6	11
105	Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients. BMC Anesthesiology, 2014, 14, 24.	1.8	50
106	A missed opportunity $\hat{a}\in$ " consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. BMC Nephrology, 2014, 15, 49.	1.8	9
107	Extracorporeal treatment for acetaminophen poisoning: Recommendations from the EXTRIP workgroup. Clinical Toxicology, 2014, 52, 856-867.	1.9	97
108	Dimethylarginines ADMA and SDMA: The Real Water-Soluble Small Toxins?. Seminars in Nephrology, 2014, 34, 97-105.	1.6	51

#	Article	IF	Citations
109	Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2008-2010.	3.0	23
110	Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS). Thrombosis and Haemostasis, 2014, 112, 365-372.	3.4	18
111	Association of Angiopoietin-2 and Dimethylarginines with Complicated Course in Patients with Leptospirosis. PLoS ONE, 2014, 9, e87490.	2.5	8
112	Chronic Kidney Disease (CKD)., 2014,, 145-150.		2
113	Quantitative MRI shows cerebral microstructural damage in hemolytic–uremic syndrome patients with severe neurological symptoms but no changes in conventional MRI. Neuroradiology, 2013, 55, 819-825.	2.2	12
114	Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations. BMC Pharmacology & Doxicology, 2013, 14, 19.	2.4	24
115	Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 455-464.	2.8	12
116	Effect of chronic elevated asymmetric dimethylarginine (ADMA) levels on granulopoiesis. Annals of Hematology, 2013, 92, 505-508.	1.8	6
117	Magnesium: the 'earth cure' of AKI?. Nephrology Dialysis Transplantation, 2013, 28, 785-787.	0.7	5
118	Tissue concentration of paraquat on day 32 after intoxication and failed bridge to transplantation by extracorporeal membrane oxygenation therapy. BMC Pharmacology & Extracorporeal membrane oxygenation therapy. BMC Pharmacology & Extracorporeal membrane oxygenation therapy. BMC Pharmacology & Extracorporeal membrane oxygenation therapy.	2.4	19
119	Increased Atherosclerotic Lesion Formation and Vascular Leukocyte Accumulation in Renal Impairment Are Mediated by Interleukin-17A. Circulation Research, 2013, 113, 965-974.	4.5	32
120	Heparinâ€grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: A prospective proofâ€ofâ€concept study. Hemodialysis International, 2013, 17, 282-293.	0.9	32
121	Symmetrical dimethylarginine is superior to NT-proBNP for detecting systemic ventricular dysfunction in adults after atrial repair for transposition of the great arteries. International Journal of Cardiology, 2013, 168, 4415-4416.	1.7	5
122	Extracorporeal membrane oxygenation instead of invasive mechanical ventilation in patients with acute respiratory distress syndrome. Intensive Care Medicine, 2013, 39, 2056-2057.	8.2	85
123	Asymmetric Dimethylarginine in Response to Recombinant Tissue-Type Plasminogen Activator and Erythropoietin in Acute Stroke. Stroke, 2013, 44, 2128-2133.	2.0	18
124	Blood–cerebrospinal fluid barrier dysfunction in patients with neurological symptoms during the 2011 Northern German E. coli serotype O104:H4 outbreak. Brain, 2013, 136, e241-e241.	7.6	9
125	Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrology Dialysis Transplantation, 2013, 28, 1434-1439.	0.7	29
126	Response to Letter Regarding Article, "Asymmetric Dimethylarginine in Response to Recombinant Tissue-Type Plasminogen Activator and Erythropoietin in Acute Stroke― Stroke, 2013, 44, e230.	2.0	1

#	Article	IF	Citations
127	Renal function and survival in 200 patients undergoing ECMO therapy. Nephrology Dialysis Transplantation, 2013, 28, 86-90.	0.7	136
128	Glucose Levels and Risk of Dementia. New England Journal of Medicine, 2013, 369, 1863-1864.	27.0	87
129	Pro: Renal replacement trauma or Paracelsus 2.0. Nephrology Dialysis Transplantation, 2013, 28, 2728-2733.	0.7	16
130	Imaging in anatomy: a comparison of imaging techniques in embalmed human cadavers. BMC Medical Education, 2013, 13, 143.	2.4	47
131	Effect of Isovolemic, Isothermic Hemodialysis on Cerebral Perfusion and Vascular Stiffness Using Contrast Computed Tomography and Pulse Wave Velocity. PLoS ONE, 2013, 8, e56396.	2.5	5
132	Angiopoietin-2 in Adults with Congenital Heart Disease and Heart Failure. PLoS ONE, 2013, 8, e66861.	2.5	27
133	Successful treatment of life threatening theophylline intoxication in a pregnant patient by hemodialysis. Clinical Nephrology, 2013, 80, 72-74.	0.7	8
134	Asymmetric Dimethyarginine as Marker and Mediator in Ischemic Stroke. International Journal of Molecular Sciences, 2012, 13, 15983-16004.	4.1	66
135	Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ, The, 2012, 345, e4565-e4565.	6.0	255
136	High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney International, 2012, 81, 314-320.	5.2	29
137	Angiopoietin-2 levels predict mortality in CKD patients. Nephrology Dialysis Transplantation, 2012, 27, 1867-1872.	0.7	71
138	Extracorporeal Treatment for Thallium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1682-1690.	4.5	41
139	Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 385-390.	4.5	43
140	The EXTRIP (<i>EXtracorporeal TReatments In Poisoning</i>) workgroup: Guideline methodology. Clinical Toxicology, 2012, 50, 403-413.	1.9	103
141	New High-Cutoff Dialyzer Allows Improved Middle Molecule Clearance without an Increase in Albumin Loss: A Clinical Crossover Comparison in Extended Dialysis. Blood Purification, 2012, 34, 246-252.	1.8	34
142	Immunoadsorption Therapy for Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. Blood Purification, 2012, 33, 1-6.	1.8	32
143	Daptomycin for a complicated urinary tract infection with vancomycin-resistant Enterococcus faecium in a renal transplant recipient. CKJ: Clinical Kidney Journal, 2012, 5, 350-351.	2.9	2
144	Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovascular Research, 2012, 96, 130-139.	3.8	79

#	Article	IF	Citations
145	The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrology Dialysis Transplantation, 2012, 27, 1454-1460.	0.7	127
146	Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrology Dialysis Transplantation, 2012, 27, 3807-3815.	0.7	209
147	Neurologic manifestations of <i>E coli</i> infection–induced hemolytic-uremic syndrome in adults. Neurology, 2012, 79, 1466-1473.	1.1	37
148	Cognitive function at 2443 νmol/l creatinine. BMC Nephrology, 2012, 13, 86.	1.8	7
149	Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. Journal of Neuroinflammation, 2012, 9, 251.	7.2	29
150	Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Experimental & Translational Stroke Medicine, 2012, 4, 24.	3.2	11
151	Circulating MicroRNAs Are Not Eliminated by Hemodialysis. PLoS ONE, 2012, 7, e38269.	2.5	48
152	Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers. PLoS ONE, 2012, 7, e38573.	2.5	9
153	Circulating microRNAs in Patients with Shiga-Toxin-Producing E. coli O104:H4 Induced Hemolytic Uremic Syndrome. PLoS ONE, 2012, 7, e47215.	2.5	9
154	Asymmetric dimethylarginine may mediate increased heat pain threshold in experimental chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 899-902.	0.7	8
155	Quantitative analysis of the antifungal drug anidulafungin by LCâ€online SPEâ€MS/MS in human plasma. Biomedical Chromatography, 2012, 26, 681-683.	1.7	2
156	Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters. International Urology and Nephrology, 2012, 44, 883-890.	1.4	8
157	Symmetrical Dimethylarginine as a Biomarker for Acute Kidney Injury. Annals of Thoracic Surgery, 2012, 93, 1763-1764.	1.3	3
158	Renal Comorbidity After Solid Organ and Stem Cell Transplantation. American Journal of Transplantation, 2012, 12, 1691-1699.	4.7	25
159	Asymmetrical Dimethylarginine - More Sensitive than NT-proBNP to Diagnose Heart Failure in Adults with Congenital Heart Disease. PLoS ONE, 2012, 7, e33795.	2.5	24
160	Symmetrical and Asymmetrical Dimethylarginine as Predictors for Mortality in Patients Referred for Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clinical Chemistry, 2011, 57, 112-121.	3.2	98
161	Obesity-related immunodeficiency in patients with pandemic influenza H1N1. Lancet Infectious Diseases, The, 2011, 11, 14-15.	9.1	42
162	Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Critical Care, 2011, 15, R80.	5.8	80

#	Article	IF	Citations
163	Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet, The, 2011, 378, 1166-1173.	13.7	134
164	ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier. The Korean Journal of Hematology, 2011, 46, 164.	0.7	9
165	High Plasma Dimethylarginine Levels are Associated with Adverse Clinical Outcome After Stroke. Journal of Atherosclerosis and Thrombosis, 2011, 18, 753-761.	2.0	45
166	High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Critical Care Medicine, 2011, 39, 184-186.	0.9	592
167	Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatment. BMC Nephrology, 2011, 12, 15.	1.8	12
168	Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrology Dialysis Transplantation, 2011, 26, 531-537.	0.7	51
169	Circulating miR-210 Predicts Survival in Critically Ill Patients with Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1540-1546.	4.5	181
170	Symmetrical Dimethylarginine Outperforms CKD-EPI and MDRD-Derived eGFR for the Assessment of Renal Function in Patients with Adult Congenital Heart Disease. Kidney and Blood Pressure Research, 2011, 34, 41-45.	2.0	33
171	Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase. Circulation, 2011, 124, 2735-2745.	1.6	58
172	Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy. Current Pharmaceutical Biotechnology, 2011, 12, 2015-2019.	1.6	28
173	TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease-a prospective follow-up study. Nephrology Dialysis Transplantation, 2011, 26, 1421-1424.	0.7	15
174	Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients-a case series. Nephrology Dialysis Transplantation, 2011, 26, 3032-3038.	0.7	18
175	Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. American Journal of Physiology - Renal Physiology, 2011, 301, F1042-F1046.	2.7	25
176	Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus, 2011, 20, 507-511.	1.6	24
177	SDMA is an early marker of change in GFR after living-related kidney donation. Nephrology Dialysis Transplantation, 2011, 26, 324-328.	0.7	53
178	Chronic renal failure alters endothelial function in cerebral circulation in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1143-H1152.	3.2	34
179	Do sea stars have low ADMA levels? High ADMA and low EPC count-duo infernal for the kidney. Nephrology Dialysis Transplantation, 2010, 25, 3138-41.	0.7	1
180	Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Medicine, 2010, 36, 462-470.	8.2	73

#	Article	IF	CITATIONS
181	Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. BMC Nephrology, 2010, 11, 19.	1.8	16
182	Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. European Journal of Clinical Investigation, 2010, 40, 294-300.	3.4	58
183	Endothelial Progenitor Cells and Cardiovascular Events in Patients with Chronic Kidney Disease – a Prospective Follow-Up Study. PLoS ONE, 2010, 5, e11477.	2.5	31
184	Removal of elevated circulating angiopoietin-2 by plasma exchange – A pilot study in critically ill patients with thrombotic microangiopathy and anti-glomerular basement membrane disease. Thrombosis and Haemostasis, 2010, 104, 1038-1043.	3.4	11
185	Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vascular Medicine, 2010, 15, 267-274.	1.5	57
186	Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. Journal of Antimicrobial Chemotherapy, 2010, 65, 1312-1314.	3.0	25
187	Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption. Scandinavian Journal of Gastroenterology, 2010, 45, 1110-1115.	1.5	9
188	Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 2571-2579.	0.7	63
189	Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysisa pharmacokinetic study. Nephrology Dialysis Transplantation, 2010, 25, 1537-1541.	0.7	62
190	Failed rescue therapy with rapamycin after paraquat intoxication. Clinical Toxicology, 2010, 48, 84-86.	1.9	8
191	Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. International Journal of Antimicrobial Agents, 2010, 35, 96-97.	2.5	17
192	Sulphobutylether- \hat{l}^2 -cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. International Journal of Antimicrobial Agents, 2010, 36, 93-94.	2.5	24
193	Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Critical Care, 2010, 14, R9.	5.8	111
194	Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension—Results from the EUTOPIA trial. Atherosclerosis, 2010, 209, 184-188.	0.8	49
195	High-dose allopurinol in patients with stable angina pectoris. Lancet, The, 2010, 376, 1298-1299.	13.7	1
196	A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients. Expert Review of Anti-Infective Therapy, 2010, 8 , 11 -14.	4.4	8
197	Extended Daily Dialysis. , 2010, , 537-545.		0
198	Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical III Patients with 2009 Influenza A (H1N1) Infection Blood, 2010, 116, 3795-3795.	1.4	0

#	Article	IF	CITATIONS
199	Back to the future: extended dialysis for treatment of acute kidney injury in the intensive care unit. Journal of Nephrology, 2010, 23, 494-501.	2.0	27
200	Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. Blood Purification, 2009, 28, 108-115.	1.8	69
201	Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrology Dialysis Transplantation, 2009, 24, 2232-2240.	0.7	48
202	The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrology Dialysis Transplantation, 2009, 24, 2179-2186.	0.7	115
203	Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysisâ€"a single case. Nephrology Dialysis Transplantation, 2009, 24, 2283-2285.	0.7	16
204	Antibiotic Dosing in Extended Dialysis. Clinical Infectious Diseases, 2009, 49, 1963-1964.	5.8	5
205	Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation. American Journal of Kidney Diseases, 2009, 53, 770-778.	1.9	64
206	Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination. BMC Nephrology, 2009, 10, 21.	1.8	28
207	PROGRESS IN UREMIC TOXIN RESEARCH: Asymmetric Dimethylarginine and Symmetric Dimethylarginine: Axis of Evil or Useful Alliance?. Seminars in Dialysis, 2009, 22, 346-350.	1.3	63
208	Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. International Journal of Antimicrobial Agents, 2009, 34, 101-102.	2.5	87
209	Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. International Journal of Antimicrobial Agents, 2009, 34, 282-283.	2.5	24
210	High caspofungin levels in alveolar cells of a lung transplant patient with suspected pulmonary aspergillosis. International Journal of Antimicrobial Agents, 2009, 34, 491-492.	2.5	10
211	Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scandinavian Journal of Infectious Diseases, 2009, 41, 155-157.	1.5	23
212	ADMA and the Brain: An Unfolding Story. American Journal of Hypertension, 2009, 22, 240-240.	2.0	6
213	Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. Journal of Hypertension, 2009, 27, 1641-1647.	0.5	56
214	Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection—Role of ethanol, hemolysis, asymmetric dimethylarginine, and the nitric oxide system. Critical Care Medicine, 2009, 37, 1483-1485.	0.9	8
215	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Critical Care Medicine, 2009, 37, 2491.	0.9	5
216	Validated high performance liquid chromatography–UV detection method for the determination of daptomycin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 875, 546-550.	2.3	55

#	Article	IF	CITATIONS
217	Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Critical Care, 2008, 12, R94.	5.8	73
218	Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Critical Care, 2008, 12, R147.	5.8	136
219	Two Cardiovascular Risk Factors in One? Homocysteine and Its Relation to Glomerular Filtration Rate. Kidney and Blood Pressure Research, 2008, 31, 259-267.	2.0	25
220	Glomerular Filtration and Coronary Flow: Is ADMA the Faucet Regulating Both?. American Journal of Hypertension, 2008, 21, 601-602.	2.0	3
221	Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrology Dialysis Transplantation, 2008, 24, 267-271.	0.7	57
222	Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2008, 17, 609-615.	2.0	60
223	L-Arginine, ADMA, SDMA, creatinine, MDRD formula: detour to renal function testing. Journal of Nephrology, 2008, 21, 959-61.	2.0	14
224	Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. Journal of Antimicrobial Chemotherapy, 2007, 61, 224-225.	3.0	39
225	Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrology Dialysis Transplantation, 2007, 23, 1061-1064.	0.7	16
226	Lowering Asymmetric Dimethylarginine – A New Mechanism Mediating the Renoprotective Effects of Renin-Angiotensin System Inhibitors in Proteinuric Patients?. Blood Purification, 2007, 25, 324-326.	1.8	7
227	Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2007, 298, 969.	7.4	2
228	Should We Measure Asymmetric Dimethylarginine in Patients with Coronary Artery Disease?. Clinical Chemistry, 2007, 53, 161-163.	3.2	10
229	A New Perspective for the Treatment of Renal Diseases?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1365-1367.	6.1	4
230	Letter by Kielstein et al Regarding Article, "High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid― Circulation, 2007, 115, e450-1; author reply e451.	1.6	3
231	The past, presence andÂfuture ofÂADMA inÂnephrology. Nephrologie Et Therapeutique, 2007, 3, 47-54.	0.5	38
232	A Novel Bioluminescent Tumor Model of Human Renal Cancer Cell Lines: An In Vitro and In Vivo Characterization. Journal of Urology, 2007, 177, 2342-2346.	0.4	8
233	Uremia., 2007,, 1278-1286.		0
234	From Zanius to ADMA: ADMA - a new "adipocytokine" and its potential role in metabolic syndrome. Journal of Nephrology, 2007, 20, 515-7.	2.0	2

#	Article	IF	Citations
235	Pharmacokinetics of Moxifloxacin and Levofloxacin in Intensive Care Unit Patients Who Have Acute Renal Failure and Undergo Extended Daily Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1263-1268.	4.5	65
236	Insulin Resistance and Renal Disease., 2006, 151, 203-211.		13
237	Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?. Current Opinion in Nephrology and Hypertension, 2006, 15, 314-320.	2.0	43
238	Response to Letter by Tsuda. Stroke, 2006, 37, 2871-2871.	2.0	1
239	Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis*. Critical Care Medicine, 2006, 34, 51-56.	0.9	141
240	Effects of asymmetric dimethylarginine (ADMA) infusion in humans. European Journal of Clinical Pharmacology, 2006, 62, 39-44.	1.9	42
241	No Benefit of Hemodiafiltration over Hemodialysis in Lowering Elevated Levels of Asymmetric Dimethylarginine in ESRD Patients. Blood Purification, 2006, 24, 439-444.	1.8	27
242	ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans. Stroke, 2006, 37, 2024-2029.	2.0	193
243	Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis. Nephrology Dialysis Transplantation, 2006, 21, 2446-2451.	0.7	309
244	Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nature Clinical Practice Nephrology, 2006, 2, 32-39.	2.0	99
245	Symmetrical Dimethylarginine. Journal of the American Society of Nephrology: JASN, 2006, 17, 1128-1134.	6.1	258
246	Cigarettes and ADMA: The Smoke Hasn't Cleared Yet. Hypertension, 2006, 48, E20; author reply E21.	2.7	6
247	Letter by Kielstein et al Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure― Circulation, 2006, 114, e242; author reply e243.	1.6	0
248	Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB Journal, 2006, 20, 994-996.	0.5	19
249	Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?. American Journal of Kidney Diseases, 2005, 46, 186-202.	1.9	157
250	Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. European Journal of Haematology, 2005, 74, 533-534.	2.2	20
251	Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1414-1418.	2.4	194
252	Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 892-898.	6.1	87

#	Article	IF	Citations
253	Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2456-2461.	6.1	295
254	Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 2432.	7.4	1
255	Renal Insulin Resistance Syndrome, Adiponectin and Cardiovascular Events in Patients with Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 1091-1098.	6.1	305
256	Subpressor Dose Asymmetric Dimethylarginine Modulates Renal Function in Humans through Nitric Oxide Synthase Inhibition. Kidney and Blood Pressure Research, 2004, 27, 143-147.	2.0	58
257	One for All – A Multi-Use Dialysis System for Effective Treatment of Severe Thallium Intoxication. Kidney and Blood Pressure Research, 2004, 27, 197-199.	2.0	18
258	A novel multimedia tool to improve bedside teaching of cardiac auscultation. Postgraduate Medical Journal, 2004, 80, 355-357.	1.8	19
259	Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans. Circulation, 2004, 109, 172-177.	1.6	375
260	Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. American Journal of Kidney Diseases, 2004, 43, 342-349.	1.9	260
261	Nitric oxide synthesis in chronic renal failure. Are plasma S-nitrosothiol levels elevated?. Clinica Chimica Acta, 2004, 339, 195-197.	1.1	4
262	A single-pass batch dialysis system: an ideal dialysis method for the patient in intensive care with acute renal failure. Current Opinion in Critical Care, 2004, 10, 483-488.	3.2	42
263	Low dialysance of asymmetric dimethylarginine (ADMA) - in vivo and in vitro evidence of significant protein binding. Clinical Nephrology, 2004, 62, 295-300.	0.7	7 5
264	CARDIOVASCULAR EFFECTS OF SYSTEMIC NITRIC OXIDE SYNTHASE INHIBITION WITH ASYMMETRIC DIMETHYLARGININE IN HUMANS. Journal of Hypertension, 2004, 22, S29.	0.5	0
265	Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. American Journal of Kidney Diseases, 2003, 42, 62-66.	1.9	116
266	Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. Journal of Chromatography A, 2003, 1013, 157-171.	3.7	91
267	Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease?. Kidney International, 2003, 63, S37-S40.	5.2	35
268	Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. European Journal of Clinical Investigation, 2003, 33, 370-375.	3.4	55
269	Efficiency of Highâ€Flux Hemodialysis in the Treatment of Valproic Acid Intoxication. Journal of Toxicology: Clinical Toxicology, 2003, 41, 873-876.	1.5	30
270	Asymmetric Dimethylarginine, Blood Pressure, and Renal Perfusion in Elderly Subjects. Circulation, 2003, 107, 1891-1895.	1.6	193

#	Article	IF	CITATIONS
271	Functional changes in the ageing kidney: is there a role for asymmetric dimethylarginine?. Nephrology Dialysis Transplantation, 2003, 18, 1245-1248.	0.7	15
272	Simulation of Abdomen Sonography. Evaluation of a New Ultrasound Simulator. Ultraschall in Der Medizin, 2003, 24, 239-244.	1.5	40
273	An uncommon cause of metabolic acidosis in a haemodialysis patient. Nephrology Dialysis Transplantation, 2002, 17, 929-930.	0.7	0
274	Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 170-176.	6.1	327
275	High-flux hemodialysis – an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clinical Nephrology, 2002, 57, 484-486.	0.7	52
276	Conversion of Goodpasture's syndrome into membranous glomerulonephritis. Nephrology Dialysis Transplantation, 2001, 16, 2082-2085.	0.7	18
277	Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney International, 2001, 59, S9-S13.	5.2	41
278	Rightâ€sided chest pain at the onset of haemodialysis. Nephrology Dialysis Transplantation, 2001, 16, 1493-1495.	0.7	15
279	ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?. Nephrology Dialysis Transplantation, 2001, 16, 1742-1745.	0.7	52
280	Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney International, 2001, 59, 9-13.	5.2	19
281	Free serum leptin but not bound leptin concentrations are elevated in patients with endâ€stage renal disease. Nephrology Dialysis Transplantation, 2000, 15, 846-850.	0.7	39
282	Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 594-600.	6.1	322
283	10. Harnsäresenkung bei niereninsuffizienten Patienten mit Hyperurikänie – Laborkosmetik oder pathophysiologisch sinnvolle Therapie?. , 0, , .		0